About
Founded in 2005 by Two Passionate Scientists
IsoTherapeutics was founded in 2005 by two entrepreneur scientists with a passion for advancing the technology of radiopharmaceuticals.
IsoTherapeutics scientists have received over 100 patents for developing chemistry and radiopharmaceutical formulations.
In April 2024 IsoTherapeutics was acquired by Telix Pharmaceuticals.
We Aid our customers and collaborators in development of pharmaceuticals.
01. Extensive Experience
Our company scientists have extensive experience in chelation and radiochemistry, which can be applied to a variety of technologies.
02. radioactive materials license
The company has a radioactive materials license to handle numerous radioisotopes of interest to the radiopharmaceutical community.
03. Conjugation & Radiolabeling
Our capabilities allow us to radiolabel proteins or antibody conjugates, which are ideal for pre-clinical proof of concept research for radio-immunotherapy and diagnostic applications.
IsoTherapeutics understands what's Important
With the increasing significance of biologics for diagnostic and therapeutic purposes in pharmaceutical applications, the ability to verify biomolecular localization in vitro and in vivo has become ever more important.
We have been closely involved in early stage analysis and proof of concept in this type of application for numerous customers. Additionally, we collaborate with a number of imaging companies and their customers to provide conjugation/radiolabeling of biologics for pre-clinical technology assessments for both diagnostic and therapeutic applications.
IsoTherapeutics opened its registered cGMP manufacturing facility equipped with clean rooms to facilitate many R&D and manufacturing opportunities. Finally, we have a wide array of analytical capabilities including GC, ICP, and HPLC with Rad, UV and RI capabilities and also a wide variety of radio-analytical counting equipment.
A close Collaboration centered on innovation
Our business model is to collaborate with companies, universities, and medical centers that complement our offerings and technologies for developing novel diagnostic and therapeutic agents for severe diseases. Current collaborators are:
